Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total Liver Disease Franchise Product Sales — Europe sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q2 2026
193
Period ended Jun 30, 2026
Change on a year earlier
+13.5%
170 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Liver Disease Franchise Product Sales — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 193 | +13.5% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 170 | +1.2% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 175 | +30.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 158 | +19.7% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 170 | +19.7% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 168 | +22.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 134 | +10.7% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 132 | +10.9% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 142 | +8.4% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 137 | -2.1% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 121 | +12.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 119 | -30.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 131 | +5.6% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 140 | +13.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 108 | – | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 170 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 124 | – | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 123 | – | Form 10-Q (filed 2023-05-03) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales — Europe sales ($M) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_total_eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.